View in EDS

Factors Impacting Survival After Transarterial Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: A Combined Analysis of the Prospective CIRT Studies

Saved in:
Bibliographic Details
Title: Factors Impacting Survival After Transarterial Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: A Combined Analysis of the Prospective CIRT Studies
Authors: Reimer, Peter, Vilgrain, Valerie, Arnold, Dirk, Balli, Tugsan, Golfieri, Rita, Loffroy, Romaric, Mosconi, Cristina, Ronot, Maxime, Sengel, Christian, Schaefer, Niklaus, Maleux, Geert, Munneke, Graham, Peynircioglu, Bora, Sangro, Bruno, Kaufmann, Nathalie, Urdaniz, Maria, Pereira, Helena, de Jong, Niels, Helmberger, Thomas
Source: Cardiovasc Intervent Radiol
Cardiovascular and interventional radiology, vol. 47, no. 3, pp. 310-324
Publisher Information: Springer Science and Business Media LLC, 2024.
Publication Year: 2024
Subject Terms: Cardiac & Cardiovascular Systems, Selective internal radiation therapy, MULTICENTER, Transarterial radioembolization, Cholangiocarcinoma, Humans, Yttrium Radioisotopes, Registries, Prospective Studies, Observational, 1102 Cardiorespiratory Medicine and Haematology, Intrahepatic cholangiocarcinoma, Clinical Investigaton, Retrospective Studies, Science & Technology, Y-90 RADIOEMBOLIZATION, INTERNAL RADIATION-THERAPY, CHEMORESISTANCE, Radiology, Nuclear Medicine & Medical Imaging, Liver Neoplasms, Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and imaging, Liver, Humans [MeSH], Prospective Studies [MeSH], Embolization, Therapeutic/methods [MeSH], Retrospective Studies [MeSH], Yttrium Radioisotopes/therapeutic use [MeSH], Bile Duct Neoplasms/radiotherapy [MeSH], Cholangiocarcinoma/radiotherapy [MeSH], Bile Ducts, Intrahepatic/pathology [MeSH], Interventional Oncology, Liver Neoplasms/radiotherapy [MeSH], Observational Studies as Topic [MeSH], CHEMOTHERAPY, DOSIMETRY, OPEN-LABEL, Embolization, Therapeutic, BILIARY-TRACT CANCER, 3. Good health, Nuclear Medicine & Medical Imaging, Observational Studies as Topic, Bile Ducts, Intrahepatic, GEMCITABINE, Bile Duct Neoplasms, Cardiovascular System & Cardiology, EXPERIENCE, 3201 Cardiovascular medicine and haematology, Life Sciences & Biomedicine
Description: Purpose Transarterial radioembolization (TARE) with Yttrium-90 resin microspheres is a treatment option for patients with intrahepatic cholangiocarcinoma (ICC). However, optimising the timing of TARE in relation to systemic therapies and patient selection remains challenging. We report here on the effectiveness, safety, and prognostic factors associated with TARE for ICC in a combined analysis of the prospective observational CIRT studies (NCT02305459 and NCT03256994). Methods A combined analysis of 174 unresectable ICC patients enrolled between 2015 and 2020 was performed. Patient characteristics and treatment-related data were collected at baseline; adverse events and time-to-event data (overall survival [OS], progression-free survival [PFS] and hepatic PFS) were collected at every follow-up visit. Log-rank tests and a multivariable Cox proportional hazard model were used to identify prognostic factors. Results Patients receiving a first-line strategy of TARE in addition to any systemic treatment had a median OS and PFS of 32.5 months and 11.3 months. Patients selected for first-line TARE alone showed a median OS and PFS of 16.2 months and 7.4 months, whereas TARE as 2nd or further treatment-line resulted in a median OS and PFS of 12 and 9.3 months (p = 0.0028), and 5.1 and 3.5 months (p = 0.0012), respectively. Partition model dosimetry was an independent predictor for better OS (HR 0.59 [95% CI 0.37–0.94], p = 0.0259). No extrahepatic disease, no ascites, and Conclusion This combined analysis indicates that in unresectable ICC, TARE in combination with any systemic treatment is a promising treatment option. Level of evidence: level 3, Prospective observational Graphic Abstract
Document Type: Article
Other literature type
File Description: application/pdf; pdf
Language: English
ISSN: 1432-086X
0174-1551
DOI: 10.1007/s00270-023-03657-x
Access URL: https://pubmed.ncbi.nlm.nih.gov/38321223
https://lirias.kuleuven.be/handle/20.500.12942/752792
https://doi.org/10.1007/s00270-023-03657-x
https://serval.unil.ch/notice/serval:BIB_2DB896B326A3
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_2DB896B326A35
https://serval.unil.ch/resource/serval:BIB_2DB896B326A3.P001/REF.pdf
https://repository.publisso.de/resource/frl:6508949
Rights: CC BY
Accession Number: edsair.doi.dedup.....49c77b626574ef951d7bc0b1f7d98caa
Database: OpenAIRE
Description
Abstract:Purpose Transarterial radioembolization (TARE) with Yttrium-90 resin microspheres is a treatment option for patients with intrahepatic cholangiocarcinoma (ICC). However, optimising the timing of TARE in relation to systemic therapies and patient selection remains challenging. We report here on the effectiveness, safety, and prognostic factors associated with TARE for ICC in a combined analysis of the prospective observational CIRT studies (NCT02305459 and NCT03256994). Methods A combined analysis of 174 unresectable ICC patients enrolled between 2015 and 2020 was performed. Patient characteristics and treatment-related data were collected at baseline; adverse events and time-to-event data (overall survival [OS], progression-free survival [PFS] and hepatic PFS) were collected at every follow-up visit. Log-rank tests and a multivariable Cox proportional hazard model were used to identify prognostic factors. Results Patients receiving a first-line strategy of TARE in addition to any systemic treatment had a median OS and PFS of 32.5 months and 11.3 months. Patients selected for first-line TARE alone showed a median OS and PFS of 16.2 months and 7.4 months, whereas TARE as 2nd or further treatment-line resulted in a median OS and PFS of 12 and 9.3 months (p = 0.0028), and 5.1 and 3.5 months (p = 0.0012), respectively. Partition model dosimetry was an independent predictor for better OS (HR 0.59 [95% CI 0.37–0.94], p = 0.0259). No extrahepatic disease, no ascites, and Conclusion This combined analysis indicates that in unresectable ICC, TARE in combination with any systemic treatment is a promising treatment option. Level of evidence: level 3, Prospective observational Graphic Abstract
ISSN:1432086X
01741551
DOI:10.1007/s00270-023-03657-x